Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies.

Strazzullo P, D'Elia L, Kandala NB, Cappuccio FP.

BMJ. 2009 Nov 24;339:b4567. doi: 10.1136/bmj.b4567. Review.

2.

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations.

Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A, Stone JA, Ur E.

Can J Cardiol. 2009 Oct;25(10):567-79. Review.

3.

Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.

Lambers Heerspink HJ, Perkovic V, de Zeeuw D.

J Hypertens. 2009 Dec;27(12):2321-31. doi: 10.1097/HJH.0b013e3283310f92. Review.

PMID:
19727007
4.

The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy.

Khan NA, Hemmelgarn B, Herman RJ, Bell CM, Mahon JL, Leiter LA, Rabkin SW, Hill MD, Padwal R, Touyz RM, Larochelle P, Feldman RD, Schiffrin EL, Campbell NR, Moe G, Prasad R, Arnold MO, Campbell TS, Milot A, Stone JA, Jones C, Ogilvie RI, Hamet P, Fodor G, Carruthers G, Burns KD, Ruzicka M, DeChamplain J, Pylypchuk G, Petrella R, Boulanger JM, Trudeau L, Hegele RA, Woo V, McFarlane P, Vallée M, Howlett J, Bacon SL, Lindsay P, Gilbert RE, Lewanczuk RZ, Tobe S; Canadian Hypertension Education Program..

Can J Cardiol. 2009 May;25(5):287-98. Review.

5.

2009 Canadian Hypertension Education Program recommendations: the scientific summary--an annual update.

Campbell NR, Khan NA, Hill MD, Tremblay G, Lebel M, Kaczorowski J, McAlister FA, Lewanczuk RZ, Tobe S; Canadian Hypertension Education Program..

Can J Cardiol. 2009 May;25(5):271-7. Review.

6.

Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials.

Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ.

Am J Med. 2009 Mar;122(3):290-300. doi: 10.1016/j.amjmed.2008.09.038.

PMID:
19272490
7.

A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial.

Feldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SA, Feagan BG.

Hypertension. 2009 Apr;53(4):646-53. doi: 10.1161/HYPERTENSIONAHA.108.123455.

8.

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.

Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlöf B; Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators..

Circulation. 2009 Feb 3;119(4):530-7. doi: 10.1161/CIRCULATIONAHA.108.826214.

9.

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.

Nephrol Dial Transplant. 2009 May;24(5):1663-71. doi: 10.1093/ndt/gfn721.

10.

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.

Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators..

N Engl J Med. 2008 Dec 4;359(23):2417-28. doi: 10.1056/NEJMoa0806182.

11.

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators., Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P.

Lancet. 2008 Sep 27;372(9644):1174-83. doi: 10.1016/S0140-6736(08)61242-8. Erratum in: Lancet. 2008 Oct 18;372(9647):1384.

PMID:
18757085
12.

Telmisartan to prevent recurrent stroke and cardiovascular events.

Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group..

N Engl J Med. 2008 Sep 18;359(12):1225-37. doi: 10.1056/NEJMoa0804593.

13.

Global burden of blood-pressure-related disease, 2001.

Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension..

Lancet. 2008 May 3;371(9623):1513-8. doi: 10.1016/S0140-6736(08)60655-8. Review.

PMID:
18456100
14.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

ONTARGET Investigators., Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C.

N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317.

16.

Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.

Weber MA, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Weir M, Kjeldsen S, Massie B, Nesbitt S, Ofili E, Jamerson K.

Blood Press. 2007;16(1):13-9.

PMID:
17453747
17.

Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP).

Cook NR, Cutler JA, Obarzanek E, Buring JE, Rexrode KM, Kumanyika SK, Appel LJ, Whelton PK.

BMJ. 2007 Apr 28;334(7599):885-8.

18.

Oral renin inhibitors.

Staessen JA, Li Y, Richart T.

Lancet. 2006 Oct 21;368(9545):1449-56. Review. Erratum in: Lancet. 2006 Dec 16;368(9553):2124.

PMID:
17055947
19.
20.
Items per page

Supplemental Content

Support Center